08:02 AM EDT, 08/16/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Friday the US Food and Drug Administration has approved IMFINZI, or durvalumab, in combination with chemotherapy for treating adult patients with resectable early-stage non-small cell lung cancer with no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

IMFINZI was generally well-tolerated, and no new safety signals observed in neoadjuvant and adjuvant settings, the company said.

AstraZeneca ( AZN ) shares rose 0.4% in Friday premarket activity.

Price: 85.19, Change: +0.29, Percent Change: +0.34